yellow2 → orange2 → red2 → brown2 → yellow2
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
3-4-CTMP
3-4-CTMP is a potent synthetic stimulant of the phenidate class with a long duration of action. It is a structural analogue of methylphenidate1, distinguished by two additional chlorine atoms on its phenyl ring.2 Although the substances have similar pharmacological profiles, their subjective effects differ. 3-4-CTMP has habit-forming properties and can lead to compulsive use.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold1-2 mg
Light2-4 mg
Moderate4-6 mg
Strong6-8 mg
Heavy6-10 mg
Duration
Onset1-2 hours
After Effects2-24 hours
Total6-18 hours
Subjective Effects
Subjective Effects not written up yet
Pharmacology
Pharmacodynamics
3,4-CTMP inhibits serotonin, norepinephrine, and dopamine reuptake by blocking their transporters, increasing the availability of these neurotransmitters between nerve cells. Its 3,4-dichloro substitution increases serotonin transporter selectivity and serotonin uptake inhibition. This substitution also increases its affinity for dopamine and norepinephrine transporters.
Pharmacokinetics
The 3,4-dichloro substitution increases resistance to metabolism and prolongs biological half-life. Low water solubility limits absorption through the nasal lining; much of an insufflated dose may instead reach the stomach through postnasal drainage.
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Many users report no noticeable acute tolerance during consecutive daily use over extended periods, with tolerance instead increasing gradually during regular, prolonged use. Some reports describe a sudden increase after a prolonged period of little change, requiring higher doses to achieve the same effects or maintain functioning.
Harm Potential
Addiction & Dependence
Psychological
3,4-CTMP is habit-forming, with reported abuse potential comparable to amphetamine or MDMA; discrimination studies have described it as more addictive than cocaine. Redosing to sustain euphoria can accumulate medically dangerous quantities because physical stimulation may outlast the psychological effects.
Toxicity
The exact toxic dose of 3,4-CTMP is unknown.
3,4-CTMP may cause potentially life-threatening pulmonary hypertension, particularly at high doses or with chronic use, while sustained receptor stimulation raises concern for heart-valve fibrosis that may cause stroke or severe, permanent heart disease. Sudden blood-pressure drops can cause dizziness, tinnitus, or fainting, particularly at high doses, and may accompany a rapid or erratic heartbeat; abnormal heart rhythms become more likely at high doses and can be serious. Strong vasoconstriction may be dangerous at high doses or in cold environments.
Anecdotal reports describe insufflated 3,4-CTMP as painful and potentially extremely caustic to the nasal mucosa.
Psychosis Risk
Stimulant psychosis is possible with prolonged abuse of 3,4-CTMP and is described as typically associated with excessive use and sleep deprivation.
History & Culture
3,4-CTMP was sold online as a designer drug1 and had a short documented history of recreational use. In 2012, it was the most…
Legality
By Country
Illegal9
United StatesIllegal (analog/blanket ban)Controlled Substances Act, 21 U.S.C. §§ 802(32), 813, 841, and 844; §§ 802(32) and 813 added by the Controlled Substance Analogue Enforcement Act of 19863536373839404114243
Under the Controlled Substances Act, 3,4-CTMP is federally covered by the controlled substance analogue provisions when it satisfies the definition in 21 U.S.C. § 802(32), falls outside the statutory exclusions, and is intended for human consumption under § 813. In those circumstances, it is treated as a Schedule I controlled substance for federal-law purposes, bringing possession under § 844 and manufacture, distribution, dispensing, and possession with intent to distribute under § 841. Sections 802(32) and 813 were added to the Act on 27 October 1986; 3,4-CTMP is not separately named in the DEA alphabetical controlled-substances list dated 27 August 2026.
CanadaIllegal3,4-CTMP is expressly listed as 3,4-dichloromethylphenidate in Schedule III, item 2(4), of the Controlled Drugs and Substances Act. The listing took effect on 5 May 2017. The Act prohibits possession, trafficking, possession for trafficking, import, export, possession for export, and production; possession, import, export, possession for export, and production may be authorized under the regulations.
ChinaIllegal3,4-CTMP is listed as item 106 in 《非药用类麻醉药品和精神药品目录》（2025年版） under the name 3,4-dichloromethylphenidate. The substance has been controlled since 1 October 2015, when the original scheduling measures and supplemental catalogue took effect. Production, trade, transport, use, storage, import, and export are prohibited; experimental research, scientific use, reference and comparison standards, and production intermediates are governed by the applicable provisions.
GermanyIllegal (analog/blanket ban)Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1 (Von 2-Phenethylamin abgeleitete Verbindungen)25262728293031
3,4-CTMP is covered by the generic structural definition for compounds derived from 2-phenethylamine in Anlage 1 Nr. 1 of the Neue-psychoaktive-Stoffe-Gesetz (NpSG), rather than by an exact-name listing. The NpSG took effect on 26 November 2016. Section 3(1) prohibits trade, placing on the market, manufacture, import, export, transit, acquisition, possession, and administration to another person. Under § 4(1), trade, placing on the market, administration to another person, and manufacture or import for the purpose of placing on the market are punishable by imprisonment for up to three years or a fine; simple acquisition and possession are not standalone criminal offenses under § 4. Recognized commercial, industrial, scientific, and official uses specified in § 3(2) are excepted, and qualifying medicinal products and narcotic drugs governed by the BtMG are excluded from the NpSG.
JapanIllegal医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第二条第十五項に規定する指定薬物及び同法第七十六条の四に規定する医療等の用途を定める省令（平成十九年厚生労働省令第十四号）第一条第百五十四号8910
3,4-CTMP and its salts are listed as designated substances under Article 1, item 154 of 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第二条第十五項に規定する指定薬物及び同法第七十六条の四に規定する医療等の用途を定める省令（平成十九年厚生労働省令第十四号）, which expressly names methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate. The designation took effect on 5 April 2014. Manufacture, import, sale, transfer, possession, purchase, acquisition, and use are prohibited when intended for, or undertaken for, purposes outside the medical and other uses permitted by ministerial ordinance.
SwedenIllegalFörordning (1992:1554) om kontroll av narkotika, bilaga 1; Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika, Förteckning I161718192021
3,4-CTMP, identified as metyl-2-(3,4-diklorofenyl)-2-(piperidin-2-yl)acetat, is expressly named as 3,4-diklorometyl-fenidat in Annex 1 to Förordning (1992:1554) om kontroll av narkotika and listed as 3,4-diklorometylfenidat in Förteckning I of Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. The Government added it to Annex 1 through SFS 2014:1480, while Läkemedelsverket added it to Förteckning I through LVFS 2014:11; both measures took effect on 16 January 2015. Förteckning I covers substances, plant materials, and fungi that normally have no medical use. Under Narkotikastrafflag (1968:64), unauthorized transfer, production for abuse, acquisition for transfer, procurement, processing, packaging, transport, storage, possession, use, sale, and offering for sale are prohibited. Separately authorized medical, scientific, especially important public-interest, and industrial channels remain available.
SwitzerlandIllegalVerordnung des EDI vom 30. Mai 2011 über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI), Anhang 6, Verzeichnis e323334
3,4-CTMP is expressly listed as 3,4-Dichlormethylphenidat in Annex 6, Verzeichnis e, of the Betäubungsmittelverzeichnisverordnung. Verzeichnis e substances are subject to the control measures applicable to Verzeichnis a narcotics and may be cultivated, manufactured, imported, exported, stored, used, or placed on the market only with authorization from the Federal Department of Home Affairs. Unauthorized conduct is punishable by up to three years' imprisonment or a monetary penalty.
TurkeyIllegal27/12/2016 tarihli ve 2016/9712 sayılı Bakanlar Kurulu Kararı eki Liste; 2313 sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun; 5237 sayılı Türk Ceza Kanunu, Madde 188 ve 191222324
3,4-Dichloromethylphenidate is expressly listed in the annex to Council of Ministers Decision No. 2016/9712, which subjects the listed substances to Law No. 2313 on the Control of Narcotic Drugs. Under Turkish Penal Code article 188, unauthorized manufacture, import, or export is punishable by twenty to thirty years' imprisonment and a judicial fine of 2,000 to 20,000 days; unauthorized sale, supply, transport, storage, purchase, acceptance, or possession is punishable by at least ten years' imprisonment and a judicial fine of 1,000 to 20,000 days. Article 191 prescribes two to five years' imprisonment for purchase, acceptance, or possession for personal use, or for use, and provides for deferred prosecution and supervised release in the circumstances stated there.
United KingdomIllegal3,4-CTMP is expressly listed as 3,4-Dichloromethylphenidate (3,4-DCMP) in Schedule 2 Part II of the Misuse of Drugs Act 1971 and has been a Class B drug since 31 May 2017. Subject to regulations made under section 7, possession, production, and supply are unlawful.
References
Citations
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-4-CTMP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
